Prader-Willi syndrome (PWS) is a rare genetic disorder that causes low muscle tone, an inability to experience hunger, and intellectual disabilities. The condition develops due to a lack of expression of genes located on chromosome 15. Currently there are no curative treatment options available for PWS. However, supportive care and medications to manage symptoms can help improve quality of life.
The Prader-Willi Syndrome (PWS) market is estimated to be valued at USD 0.916 Bn in 2024 and is expected to reach USD 1.47 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2031.
Key Takeaways
Key players operating in the Prader-Willi Syndrome (PWS) Therapeutics are Chongqing Huapont Pharmaceutical, Sino Biopharmaceutical, NLS Pharmaceutics, Anthropic and Dicerna Pharmaceuticals.

Growing awareness about Prader-Willi Syndrome (PWS) Treatment Market and demand for new treatment options to manage the condition is expected to drive market growth. Companies are investing in research and development to develop more effective drug therapies and gene therapies which can potentially cure PWS.
Market Trends
The development of novel drug therapies is one of the key trends in the PWS therapeutics market. Companies are developing new classes of drugs such as oxytocin receptor antagonists and growth hormone secretagogues to address specific symptoms associated with PWS. Gene therapies hold promise to cure PWS and companies are developing adeno-associated virus vectors to deliver functional copies of the SNORD116 cluster.
Market Opportunities
The lack of curative options for PWS presents a major opportunity for companies developing gene therapies for the condition. Currently, PWS primarily impacts children and young adults, however, as life expectancy increases, the market potential over the long term also rises. More clinical research on newer drug candidates can help address unmet needs and drive market growth.
Impact of COVID-19 on Prader-Willi Syndrome (PWS) Market Growth
The COVID-19 pandemic has impacted the growth of the PWS market. During the pandemic, people with PWS faced challenges in getting regular medical care and therapeutics due to lockdowns and restrictions on non-essential medical services. This led to disruptions in treatment continuity and worsening of symptoms for many patients. It also delayed the clinical trials and drug development process for new treatment options.
However, the demand for home healthcare services saw an increase as patients preferred receiving care and therapeutics at home to avoid risks of COVID-19 exposure. Telehealth and digital health solutions also emerged as valuable tools for remote monitoring of patients and ensuring treatment adherence. With remote working becoming mainstream, pharmaceutical companies accelerated their drug discovery and development activities using digital technologies.
As restrictions ease now with declining COVID-19 cases, the market is regaining lost growth momentum. Healthcare services are resuming fully while maintaining necessary safety protocols. Companies are focusing on new product launches and capacity expansions to fulfill the growing needs of the patient population. Both patients and healthcare providers have also recognized the importance of advanced telehealth solutions for effective long-term care of chronic diseases like PWS going forward.
The United States accounts for the largest share of the global PWS market currently in terms of value, followed by major European countries like Germany, France, and the United Kingdom. This is owing to the large diagnosed patient pool, higher healthcare spending, and well-established reimbursement structure in these regions. However, Asia Pacific is emerging as the fastest growing regional market with improving access to diagnosis and treatment in countries like China, India, and Japan. Rising medical tourism from other countries is also contributing to the growth of the PWS market in Asia Pacific.

Get more insights on - Prader-Willi Syndrome (PWS) Therapeutics Market

Get this Report in Japanese Language: プラダーウィリ症候群（PWS）治療市場

Get this Report in Korean Language:  프라더윌리증후군(PWS) 치료 시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163